Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to explain what areas will be driving Teva forward while sharing his views on the French generic and biosimilar environment.
Overall, the most difficult stages of restructuring are behind us and we are moving forward with the new Teva to reach out and reengage our employees while maintaining the trust of our customers
